References
[1] . 2000;342:1334-1349.
[2] Fanelli et al. Acute respiratory distress syndrome: new
definition, current and future therapeutic options. J Thorac Dis
2013;5(3):326-334.
[3] Swaroopa et
al. Association of serum interleukin-6, interleukin-8, and Acute
Physiology and Chronic Health Evaluation II score with clinical outcome
in patients with acute respiratory distress syndrome. Indian J Crit
Care Med. 2016; 20(9):518-525.
[4] Didion SP. Cellular and oxidative mechanisms associated with
interleukin-6 signaling in the vasculature. Int J Mol Sci. 2017; 18,
2563.
[5] Park WY, Goodman RB, Steinberg KP. Cytokine balance in the lungs
of patients with acute respiratory distress syndrome. Am J Respir Crit
Care Med. 2001;164:1896–1903.
[6] Meduri GU, Headley S, Kohler G, et al. Peristent elevation of
inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta
and IL-6 levels are consistent and efficient predictors of outcome over
time. Chest. 1995;107:1062–1073.
[7] Ding C, Jones G. Technology evaluation: MRA, Chugai. Current
Opinion in Molecular Therapeutics. 2003; 5(1):64-69.
[8] Ito H. IL-6 and Crohn’s Disease. Curr Drug Targets Inflamm
Allergy. 2003; 2(2):125-30.
[9] Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen
receptor T cell therapy–assessment and management of toxicities. Nat
Rev Clin Oncol. 2018;15(1):47.
[10] Khadka, Sakemura, Kenderian, Johnson. Management of cytokine
release syndrome: an update on emerging antigen-specific T cell engaging
immunotherapies. Immunotherapy. 2019;11(10):851-857.
[11] Cross LJM, Matthay MA. Biomarkers in acute lung injury:
insights into pathogenesis of acute lung injury. Crit Care Clin. 2011
April;27(2):355–377.
[12] Parsons PE, Eisner MD, Thompson BT, et al. Lower tidal volume
ventilation and plasma cytokine markers of inflammation in patients with
acute lung injury. Crit Care Med. 2005;33:1–6.
[13] Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The Pro-
And Anti-Inflammatory Properties of the Cytokine interleukin-6. Biochim
Piophys Acta. 2011; 1813(5): 878-88.
[14] Chalaris A, Rabe B, Paliga K, et al. Apoptosis is a natural
stimulus of IL6R shedding and contributes to the pro-inflammatory
trans-signaling function of neutrophils. Blood. 2007;110:1748–1755.
[15] Rabe B, Chalaris A, May U, et al. Transgenic blockade of
interleukin 6 transsignaling abrogates inflammation. Blood.
2008;111:1021–1028.
[16] Becker C, Fantini MC, Schramm C, et al. TGF-beta suppresses
tumor progression in colon cancer by inhibition of IL-6 trans-signaling.
Immunity. 2004;21:491–501.
[17] Chen Q, Fisher DT, Clancy KA, et al. Fever-range thermal stress
promotes lymphocyte trafficking across high endothelial venules via an
interleukin 6 trans-signaling mechanism. Nat Immunol. 2006;7:1299–1308.
[18] Oberg HH, Wesch D, Grussel S, Rose-John S, Kabelitz D.
Differential expression of CD126 and CD130 mediates different STAT-3
phosphorylation in CD4+CD25- and CD25 high regulatory T cells. Int
Immunol. 2006;18:555–563.
[19] Rose-John S, Waetzig GH, Scheller J, Grotzinger J, Seegert D.
The IL-6/sIL-6R complex as a novel target for therapeutic approaches.,
Expert Opin Ther Targets. 2007;11;613–624.
[20] Scheller J, Rose-John S. Interleukin-6 and its receptor: from
bench to bedside. Med Microbiol Immunol. 2006;195:173–183.
[21] Jostock T, Müllberg J, Özbek S, et al. Soluble gp130 is the
natural inhibitor of soluble IL-6R transsignaling responses. Eur J
Biochem. 2001;268:160–167.
[22] Rose-John. IL-6 trans-signaling via the Soluble il-6 receptor:
importance for the pro-inflammatory activities of IL-6. Int J Biol Sci.
2012;8(9):1237-1247.
[23]
Sylvant
Highlights of Prescribing Information.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125496s000lbl.pdf
[24] . Int. J. Cancer. 2004; 111: 592-595.
[25] Le RQ et al., FDA Approval Summary: Tocilizumab for Treatment
of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening
Cytokine Release Syndrome. The Oncologist 2018; 23:943-947.
[26] Gibiansky and Frey. Linking interleukin-6 receptor blockade
with tocilizumab and its hematological effects using a modeling
approach. J Pharmacokinet Pharmacodyn. 2012; 39:5-16.
[27] Tabrizi M,
Bornstein GG, Suria H. Biodistribution mechanisms of therapeutic
monoclonal antibodies in health and disease. The AAPS Journal. 2010;
12(1): 33-43.
[28] Channappanavar and Perlman. Pathogenic human coronavirus
infections: causes and consequences of cytokine storm and
immunopathology. Semin Immunopathol. 2017; 39:529-539.
[29] Peiris JS et al. Clinical progression and viral load in a
community outbreak of coronavirus-associated SARS pneumonia: a
prospective study. Lancet 2003; 361(9371):1767–1772.
[30] Al-Tawfiq JA, et al. Middle East respiratory syndrome
coronavirus: a case-control study of hospitalized patients. Clin Infect
Dis. 2014;59(2):160–165.
[31] Arabi YM, et al. Clinical course and outcomes of critically ill
patients with Middle East respiratory syndrome coronavirus infection.
Ann Intern Med. 2014;160:389–397.
[32] Gu J, et al. Multiple organ infection and the pathogenesis of
SARS. J Exp Med. 2005;202(3):415–424.
[33] Ng DL, et al. Clinicopathologic, immunohistochemical, and
ultrastructural findings of a fatal case of Middle East respiratory
syndrome coronavirus infection in the United Arab Emirates, April 2014.
Am J Pathol. 2016;186(3):652–658.
[34] Falzarano D, et al. Treatment with interferon-alpha2b and
ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat
Med. 2013;19(10):1313–1317.
[35] Omrani AS, et al. Ribavirin and interferon alfa-2a for severe
Middle East respiratory syndrome coronavirus infection: a retrospective
cohort study. Lancet Infect Dis. 2014;14(11):1090–1095.
[36] WHO R&D Blueprint: Covid 19: Informal consultation on the
potential role of IL-6/IL-1 antagonists in the clinical management of
COVID 19 infection.
[37] Regeneron and Sanofi Provide Update on US Phase 2/3
Adaptive-Designed Trial of Kevzara® (Sarilumab) in Hospitalized COVID-19
Patients. News Release. Regeneron; April 27, 2020. Accessed April 27,
2020. https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-provide-update-us-phase-23-adaptive.
[38] van Zaanen HC, Koopmans RP, Aarden LA, Rensink HJ, Stouthard
JM, Warnaar SO, Lokhorst HM, van Oers MH.J Clin Invest. Endogenous
interleukin 6 production in multiple myeloma patients treated with
chimeric monoclonal anti-IL6 antibodies indicates the existence of a
positive feed-back loop.1996 Sep 15;98(6):1441-8.
[39] Deisseroth A, Ko CW, Nie L, Zirkelbach JF, Zhao L, Bullock J,
Mehrotra N, Del Valle P, Saber H, Sheth C, Gehrke B, Justice R, Farrell
A, Pazdur R. FDA Approval: Siltuximab for the Treatment of Patients with
Multicentric Castleman Disease. Clin Cancer Res. 2015 Mar 1;21(5):950-4.
[40] Wang, W., Wang, X., Doddareddy, R. et al. Mechanistic
Pharmacokinetic/Target Engagement/Pharmacodynamic (PK/TE/PD) Modeling in
Deciphering Interplay Between a Monoclonal Antibody and Its Soluble
Target in Cynomolgus Monkeys. AAPS J 2014; 16, 129–139.
[41] Mihara M, Kasutani K, Okazaki M, Nakamura A, Sawai S, Sugimoto
M, Matsumoto Y, Ohsugi Y. Tocilizumab inhibits signal transduction
mediated by both mIL-6R and sIL-6R, but not by the receptors of other
members of IL-6 cytokine family. International Immunopharmacology 2005;
5(12): 1731-1740.